MERMAID-1
A lung cancer trial that planned to test whether adding the immunotherapy durvalumab to chemotherapy after surgery helps people whose blood shows leftover tumour DNA; the registry lists it as complete with 89 participants.
Overview
MERMAID-1 was AstraZeneca's phase 3, double-blind trial of adjuvant durvalumab with platinum chemotherapy in completely resected stage II to III non-small-cell lung cancer, designed around ctDNA-detected minimal residual disease. The registry records a start on 17 July 2020, a status of completed and 89 participants, with primary and study completion on 31 August 2023. Together with MERMAID-2 it is the main example that a ctDNA-selected escalation trial can be hard to run in lung cancer, where adjuvant immunotherapy was approved for all-comers while the trials were recruiting.
Similar pages
not linked directly; found by shared links- TrialTRACC
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag ctdna-roadmap.
- TrialBESPOKE CRC
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag ctdna-roadmap.
- TrialCIRCULATE-US
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing and the tag ctdna-roadmap.
- TrialVanguard Study (NCI Cancer Screening Research Network)
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Liquid biopsy (ctDNA) and the tag ctdna-roadmap.
- PersonAsh A. Alizadeh
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- PersonSarah-Jane Dawson
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- PersonMaximilian Diehn
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Non-small-cell lung cancer.
- TreatmentOncodetect
Shares Circulating tumour DNA (ctDNA), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).